Scientific Study

Access to over 2,900 scientific references, studies and publications. This section is constantly updated with studies that have been published in scientific journals.

Back
Products: Peanuts
Subject: Allergy

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Children with Atopic Comorbidities

Authors: Scurlock, A. M., Fleischer, D. M., Toit, G. D., Arends, N. J. T., Pongracic, J. A., Trujillo, J., Turner, P., Vogelberg, C., Bee, K. J., Green, T. D., Meney, J., Bois, T., Campbell, D. E., Sampson, H. A., & Burks, A. W.
  • Journals: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • Pages: S1081-1206(25)00179-6
  • Year: 2025
Background: There is a high prevalence rate of atopic comorbidities, including atopic dermatitis (AD), asthma, and concomitant food allergy (CFA), in children with peanut allergy. Objective: To evaluate whether concomitant atopic comorbidities affect the safety and efficacy of VIASKIN® peanut patch (VP250). Methods: EPITOPE was a phase 3, double-blind, placebo-controlled trial designed to assess treatment response to VP250, as measured by eliciting dose at 12 months, in peanut-allergic children aged 1 through 3 years. This subgroup analysis assessed response rates for prespecified subgroups, including children with asthma, AD/eczema, and CFA. The safety profile of VP250 was evaluated by atopic condition in all randomized participants who received at least 1 dose. Results: Responder rates were significantly greater with VP250 vs placebo, irrespective of the presence of atopic conditions. There was no significant interaction effect between participants with an atopic comorbidity vs those without. The safety profile was generally similar across subgroups without any additional safety signals. There was no clinically meaningful change in severity of AD in those receiving VP250, regardless of baseline AD status. Rates of anaphylaxis were higher in those with AD or CFA receiving VP250 vs those without; however, these imbalances were also observed in the placebo group. Conclusion: The results suggest that 12 months of treatment with VP250 was effective in desensitizing peanut-allergic children aged 1 through 3 years, with no difference in efficacy and a favorable safety profile, regardless of the presence of atopic comorbidities.

https://doi.org/10.1016/j.anai.2025.04.002